Introduction
When most people think about cancer testing, they think about looking for something specific. A mutation, a protein, a genetic change. The tests we explored in our previous articles largely work this way: they scan a tumor for a known target and tell you whether it is there or not.
But what if the most important thing about a tumor is not a single change, but the overall pattern of how it is behaving? That is the idea behind gene expression panels, and it represents a meaningful shift in how we understand and treat certain cancers.
Genes Are Not Just Switches, They Are Dials
Every cell in your body contains the same DNA, the same set of instructions. But not all cells behave the same way. A liver cell and a skin cell contain identical genetic code, yet they look completely different and do completely different things. That is because genes can be turned on or off, and they can be active at different levels depending on the cell and the circumstances.
In cancer, these patterns of gene activity can become abnormal. Some genes that should be quiet become overactive, driving aggressive tumor behaviour. Others that should be working get switched off. The overall pattern tells a story about how the tumor is functioning, how quickly it may grow, and sometimes how it will respond to treatment.
Gene expression panels are designed to read that story.
How Do They Work?
When a tumor sample is collected, scientists measure which genes are active and how active they are. The specific genes included in a panel are chosen because research has shown they are linked to important clinical outcomes, such as whether a tumor is likely to return after treatment or respond to chemotherapy.
Rather than giving a simple positive or negative result, these panels typically produce a score or a classification. That result is then used alongside other clinical information to help guide treatment decisions.
What Do They Look Like in Practice?
The best-known examples come from breast cancer. Tests like Oncotype DX and MammaPrint analyse the activity of dozens of genes within a tumor to assess how likely the cancer is to return or spread. Think of it a little like a weather forecast for the cancer. Rather than guessing based on how the clouds look, you are getting a reading from instruments that go much deeper.
For patients with early-stage breast cancer, these panels have been genuinely life-changing. Large clinical trials have shown that many patients who would previously have been recommended chemotherapy based on traditional factors actually have tumors that are unlikely to return, and that chemotherapy would not have helped them. For those patients, a gene expression panel provides the evidence needed to safely skip chemotherapy altogether, sparing them from significant side effects and disruption to their lives.
A test called Prosigna, which is built on a gene set known as PAM50, takes a slightly different approach. Rather than scoring recurrence risk, it classifies tumors into biological types based on how they behave. Two tumors that look identical under a microscope can have very different personalities biologically, and Prosigna helps reveal those differences. That distinction can change the entire treatment approach.
Gene expression panels are also beginning to make an impact beyond breast cancer. Thyroid GuidePx®, developed by Qualisure Diagnostics, applies the same principle to papillary thyroid cancer, the most common type of thyroid cancer. It analyses the activity of 82 genes and classifies tumors into three molecular subtypes, each reflecting a different level of recurrence risk. This helps clinicians identify which patients have low-risk tumors that may be safely managed with more conservative treatment, and which patients have higher-risk features that warrant a more aggressive approach.
Why This Matters
Gene expression panels add a layer of insight that traditional testing simply cannot provide. They help doctors move beyond what a tumor looks like and start understanding what it is actually doing. The result is more confident treatment decisions, fewer unnecessary treatments, and care that is genuinely tailored to the individual patient.
The principle behind gene expression panels is not limited to breast cancer. As the field grows, tests like Thyroid GuidePx® are bringing the same depth of biological insight to other cancer types, helping clinicians make more informed decisions for more patients.
In our next article, we will look at how these ideas apply in thyroid cancer, where understanding tumor biology has the potential to spare patients from unnecessary surgery and guide more personalised care.